Sanofi shares are trading higher after the company's Phase 2/3 trial of Kevzara with Regeneron met its primary endpoint. NOTE: The drug showed potential for treating the sickest coronavirus patients, but less benefit in patients with less-advanced disease.
Benzinga Newsdesk